Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Harvard Business School
Boehringer Ingelheim

Last Updated: December 14, 2019

DrugPatentWatch Database Preview

Drugs in Development Information for BMY-14802

Join the DrugPatentWatch Referral Program
Get access to a free drug patent landscape report or a free one-month subscription

« Back to Dashboard

What is the drug development status for BMY-14802?

BMY-14802 is an investigational drug.

There have been 8 clinical trials for BMY-14802. The most recent clinical trial was a Phase 2 trial.

The most common disease conditions in clinical trials are HIV Infections, AIDS-Related Complex, and Infection. The leading clinical trial sponsors are Bristol-Myers Squibb, National Institute of Allergy and Infectious Diseases (NIAID), and Northwestern University.

Recent Clinical Trials for BMY-14802
Rebeccamycin Analogue in Treating Patients With Refractory Stage III or Stage IV Ovarian Epithelial CancerNational Cancer Institute (NCI)Phase 2
Rebeccamycin Analogue in Treating Patients With Refractory Stage III or Stage IV Ovarian Epithelial CancerNorthwestern UniversityPhase 2
A Phase II Efficacy Study Comparing 2',3'-Dideoxyinosine (ddI) (BMY-40900) and Zidovudine Therapy of Patients With HIV Infection Who Have Been on Long Term Zidovudine TreatmentBristol-Myers SquibbPhase 2

See all BMY-14802 clinical trials

Clinical Trial Summary for BMY-14802

Top disease conditions for BMY-14802
Top clinical trial sponsors for BMY-14802

See all BMY-14802 clinical trials

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.